No reviews yet. Be the first to rate Masaki!
Kyoto University and Chordia Therapeutics unveil CTX-439, a CDK12 inhibitor enhancing PARP therapy in uterine serous carcinoma via HRD induction. Preclinical promise for Japan's rising endometrial cancer challenge.
Photo by Ling App on Unsplash
Photo by Hermes Rivera on Unsplash
Photo by Maccy on Unsplash
Photo by Chanelle on Unsplash
Photo by Marek Pavlík on Unsplash
Photo by World Wanderer on Unsplash
Photo by Artfox Photography on Unsplash
See Research & Publication News in Your CountrySee more Research & Publication News Articles
Have a story or a research paper to share? Become a contributor and publish your work on AcademicJobs.com.
Submit your Research - Make it Global News